Dr. Ron’s Research Review – March 15, 2017

©

This week’s research review focuses on topical nicotinamide for seborrheic dermatitis.

A study published in the Journal of Dermatology Treatment evaluated the efficacy of topical nicotinamide (4% cream) in 48 patients with mild to moderate seborrheic dermatitis of the face (36 males and 12 females; age 20-50 years). Clinical measures were assessed by erythema, scaling, and infiltration, which were evaluated using a four-point scale 0-3 before starting treatment and after 2, 6, and 12 weeks' therapy. 
In comparison with baseline, a reduction of 75% of the total score was observed in patients treated with nicotinamide, whereas for placebo-treated patients the reduction was of 35% (p < 0.05).  (Fabbrocini et al., 2014)

Dr. Ron


 

Articles

Topical nicotinamide for seborrheic dermatitis: an open randomized study.
            (Fabbrocini et al., 2014) Download
BACKGROUND:  Treatment of seborrheic dermatitis (SD) includes various options with different success and safety limitations. OBJECTIVE:  To evaluate the efficacy of topical nicotinamide (NCT) in the treatment of SD. METHODS:  A total of 48 patients with mild to moderate SD of the face were enrolled in the study (36 males and 12 females; age 20-50 years). Patients were randomized into two groups A and B, who were treated once a day with topical administration of NCT 4% cream and with the vehicle without NCT (placebo), respectively. Clinical measures were assessed by erythema, scaling, and infiltration, which were evaluated using a four-point scale 0-3 before starting treatment and after 2, 6, and 12 weeks' therapy. RESULTS:  In comparison with baseline, a reduction of 75% of the total score was observed in patients treated with NCT, whereas for placebo-treated patients the reduction was of 35% (p < 0.05). CONCLUSION:  Topical NCT 4% can have a potential for the treatment of SD.

References

Fabbrocini, G, M Cantelli, and G Monfrecola (2014), ‘Topical nicotinamide for seborrheic dermatitis: an open randomized study.’, J Dermatolog Treat, 25 (3), 241-45. PubMed: 23763270